Team Introductions: The Memorial Sloan Kettering “Yankees” vs The Dana-Farber “Red Sox”

Idecabtagene vicleucel led to high rates of MRD negativity in multiple myeloma who responded did not have complete responses to first-line therapy.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

During the 66th American Society of Hematology Annual Meeting and Exposition, experts in multiple myeloma gathered to discuss the impact of maintenance therapy and minimal residual disease (MRD) in patients with newly diagnosed transplant-eligible or -ineligible multiple myeloma.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Efficacy results from the phase 1/2 LINKER-MM1 trial evaluating linvoseltamab in relapsed or refractory multiple myeloma support the decision.

Hematologists gathered to discuss recent updates on bispecific antibodies surrounding patients with relapsed/refractory multiple myeloma.